GLP-1 Agonist Therapy Center

Dulaglutide shows efficacy in diabetes patients with poor glycemic control already taking multiple oral medications…. Patients with uncontrolled diabetes already taking multiple oral agents often require insulin therapy for better glycemic control but insulin therapy is associated with hypoglycemia and weight gain. Dulaglutide, approved by the FDA in September 2014, …

FREEDOM-1 and FREEDOM-1 High Baseline (HBL) study showed positive results when the continuous subcutaneous infusion of exenatide is added to standard oral diabetes medications….  ITCA 650 is a continuous subcutaneous infusion of exenatide through a pump for the treatment of type 2 diabetes. FREEDOM-1 is a double blinded, randomized, placebo-controlled, multicenter, phase …

Dulaglutide (Trulicity) is approved as a once-weekly injection for the treatment of type 2 diabetes…. Dulaglutide is a member of the glucagon-like peptide (GLP-1) receptor agonist class, along with liraglutide, exenatide, and albiglutide. The US Food and Drug Administration (FDA) has approved dulaglutide (Trulicity) as a once a week injection …

Using a GLP-1 agonist with insulin may be the most effective therapy combination for lowering HbA1c in type 2 diabetes patients…. Researchers performed a systematic review and pooled meta-analysis of randomized controlled trials published between January 1, 1950 and July 29, 2014. Out of the 2,905 studies that were identified, …

It is always interesting when you two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes. I had the opportunity to review a conversation that John …

When Steve and Andrew got back from the ADA’s 74th Scientific Sessions in San Francisco, we put together an awesome overview of some of the new research and studies on GLP-1. Now that we have had some time to review the entire program we are providing you with more of …

For this month’s special feature we have a selection of the GLP-1 abstracts and releases from the recent American Diabetes Association’s 74th Scientific Sessions in San Francisco. New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes New Phase 3a findings show IDegLira, the …

The cardiovascular morbidity and mortality associated with diabetes are well established, so much so that type 2 diabetes has been described as a cardiovascular disease presenting as a metabolic disorder. Patients with type 2 diabetes are particularly at risk for atherosclerosis; so medications with ancillary vascular benefits are particularly useful, …

Under normal conditions, the liver plays a critical role in disposing of orally or enterally delivered carbohydrate and therefore in limiting postprandial hyperglycemia. We often think that this response involves only a decrease in hepatic glucose production however there are many studies showing that there is also a stimulation of …

The Food and Drug Administration (FDA) has approved albiglutide (Tanzeum, GlaxoSmithKline), a once-weekly injectable glucagonlike peptide 1 (GLP-1) receptor agonist to treat type 2 diabetes…. “Tanzeum is a new treatment option for the millions of Americans living with type 2 diabetes,” Curtis Rosebraugh, MD, MPH, director of the Office of …